Kevin Hong

1.2k total citations
32 papers, 798 citations indexed

About

Kevin Hong is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kevin Hong has authored 32 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 16 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Kevin Hong's work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (7 papers) and Heat shock proteins research (6 papers). Kevin Hong is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (7 papers) and Heat shock proteins research (6 papers). Kevin Hong collaborates with scholars based in United States, Germany and Spain. Kevin Hong's co-authors include An‐Cheng Huang, Pengcheng Luan, Marcus F. Boehm, S.K. Huang, Paul R. Stauffer, Demetrios Papahadjopoulos, Hongli Zhu, Chao Liu, Srinivas Rao Kasibhatla and Theodore L. Phillips and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kevin Hong

31 papers receiving 771 citations

Peers

Kevin Hong

RESE

BIOMA

Mamoru Hatakeyama Japan

Yusuke Kagawa Japan

Abhalaxmi Singh India

Jinqiu Chen China

Ge Huang China

Wenqian Li China

Аlyssa M. Master United States

Pilar Acedo United Kingdom

Adolfo I. B. Romo United States

Marina Pöttler Germany

Mamoru Hatakeyama Japan

Kevin Hong

506 ×1.3

31 ×0.2

RESE

84 ×0.8

BIOMA

149 ×1.4

72 ×0.7

Citations per year, relative to Kevin Hong Kevin Hong (= 1×) peers Mamoru Hatakeyama

Countries citing papers authored by Kevin Hong

Since Specialization

Citations

This map shows the geographic impact of Kevin Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Hong more than expected).

Fields of papers citing papers by Kevin Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Hong. The network helps show where Kevin Hong may publish in the future.

Co-authorship network of co-authors of Kevin Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Hong. A scholar is included among the top collaborators of Kevin Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Hong. Kevin Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lonial, Sagar, Meletios Α. Dimopoulos, Jesús G. Berdeja, et al.. (2025). EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncology. 21(14). 1761–1769.

Oriol, Albert, Meletios Α. Dimopoulos, Fredrik Schjesvold, et al.. (2023). Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment. Clinical Lymphoma Myeloma & Leukemia. 24(3). 165–176.e4. 1 indexed citations

Donk, Niels W.C.J. van de, Darrell White, Brea Lipe, et al.. (2023). P-320 Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial. Clinical Lymphoma Myeloma & Leukemia. 23. S214–S215. 1 indexed citations

White, Darrell, Brea Lipe, Mercedes Gironella, et al.. (2023). OA-41 Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial. Clinical Lymphoma Myeloma & Leukemia. 23. S25–S25. 3 indexed citations

Hong, Kevin, et al.. (2022). The Effects of Machine-powered Platform Governance: An Empirical Study of Content Moderation. Proceedings of the ... Annual Hawaii International Conference on System Sciences. 5 indexed citations

Amatangelo, Michael, Yiming Cheng, William E. Pierceall, et al.. (2022). P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL. HemaSphere. 6. 758–759. 2 indexed citations

Amatangelo, Michael, Yiming Cheng, William E. Pierceall, et al.. (2022). P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial. Clinical Lymphoma Myeloma & Leukemia. 22. S162–S162. 2 indexed citations

Lonial, Sagar, Jesús G. Berdeja, Meletios Α. Dimopoulos, et al.. (2021). P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S150–S150. 1 indexed citations

Amatangelo, Michael, Chad C. Bjorklund, Peilin Ma, et al.. (2020). Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations. Blood. 136(Supplement 1). 9–10. 7 indexed citations

10.

Hong, Kevin, et al.. (2016). Multiple Myeloma: Concise Review of the Literature and A Case Report of Mandibular Involvement. International Journal of Dentistry and Oral Science. 309–314. 1 indexed citations

11.

Siegel, David S., Katja Weisel, Meletios Α. Dimopoulos, et al.. (2016). Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia & lymphoma. 57(12). 2833–2838. 21 indexed citations

12.

Moreau, Philippe, Katja Weisel, Kevin Song, et al.. (2016). Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leukemia & lymphoma. 57(12). 2839–2847. 10 indexed citations

13.

Siegel, David S., Katja Weisel, Meletios Α. Dimopoulos, et al.. (2015). Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. Blood. 126(23). 3031–3031. 3 indexed citations

14.

Hong, Kevin, et al.. (2014). Directed Polyvalent Display of Sulfated Ligands on Virus Nanoparticles Elicits Heparin-Like Anticoagulant Activity. Bioconjugate Chemistry. 25(8). 1444–1452. 13 indexed citations

15.

Hong, Kevin, et al.. (2013). The relationship between castor bean stem diameter and extrafloral nectary gland size. BIOS. 84(2). 98–100. 1 indexed citations

16.

Lundgren, Karen, Hong Zhang, Nanni Huser, et al.. (2009). BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics. 8(4). 921–929. 140 indexed citations

17.

Lundgren, Karen, Hong Zhang, Adeela Kamal, et al.. (2007). BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models. 6. 3 indexed citations

18.

Lundgren, Karen, Adeela Kamal, Rachel Lough, et al.. (2006). CNF2024 - The first clinical stage synthetic oral Hsp90 inhibitor. Cancer Research. 66. 1142–1142. 1 indexed citations

19.

Biamonte, Marco A., Jiandong Shi, Kevin Hong, et al.. (2005). Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90. Journal of Medicinal Chemistry. 49(2). 817–828. 50 indexed citations

20.

Huang, S.K., Paul R. Stauffer, Kevin Hong, et al.. (1994). Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.. PubMed. 54(8). 2186–91. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact